Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


Our top-notch dedicated system is used to design specialised libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
P15086

UPID:
CBPB1_HUMAN

ALTERNATIVE NAMES:
Pancreas-specific protein

ALTERNATIVE UPACC:
P15086; O60834; Q53XJ0; Q96BQ8

BACKGROUND:
The enzyme Carboxypeptidase B, recognized by its alternative name Pancreas-specific protein, is integral to the enzymatic cascade involved in protein catabolism. It specifically targets and cleaves the C-terminal amino acid from peptide chains, facilitating nutrient absorption and utilization. The unique identifier for this protein is P15086.

THERAPEUTIC SIGNIFICANCE:
Exploring the functionality of Carboxypeptidase B holds promise for the development of novel therapeutic approaches. Given its essential role in the digestive process, targeting this enzyme could offer new avenues for treating digestive disorders and enhancing nutrient uptake.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.